24 May 2013
Keywords: new, study, confirms, zomig, long-term, safety, astrazeneca
Article | 31 January 2005
AstraZeneca's Zomig (zolmitriptan) nasal spray is well-tolerated for the treatment of migraine during long-term use of up to one year, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
31 January 2005
© 2013 thepharmaletter.com